New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
12:33 EDTINOInovio prepping for failure of cervical cancer vaccine study, TheStreet says
With results due "any day" from Inovio Pharmaceuticals' phase II study of its vaccine for cervical pre-cancerous lesions, the company's CEO is "walking back expectations" and "laying the foundation for a massive spin job," according to TheStreet's Adam Feuerstein. The author said he suspects Inovio already has data in hand and that recent "red flags" by CEO Joseph Kim and the company may be intended to "cushion the vaccine's failure." Reference Link
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
05:33 EDTINOInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use